Stocktwits on MSN
REPL stock on track for worst drop in nearly 7 months ahead of FDA decision on skin cancer drug
The FDA issued a complete response letter regarding the application for RP1 in combination with Nivolumab for the treatment of advanced melanoma in late July. ・Following months of engagement between ...
Stocktwits on MSN
IOVA stock clocks best session since February as retail awaits FDA decision on rival drug
FDA is slated to decide on potential rival Replimune’s application for RP1 in the treatment of advanced melanoma by April 10. ・Iovance’s Amtagvi cellular therapy is already approved as a treatment for ...
We recently published 10 Stocks Losing Big Amid Market Boom. Replimune Group, Inc. (NASDAQ:REPL) is one of the worst performers on Thursday. Replimune extended losses to a second consecutive day on ...
Replimune Group (REPL) has drawn attention after presenting updated clinical data from its IGNYTE phase 2 trial at the ESMO Congress 2025. The study combined RP1 with nivolumab in patients with acral ...
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in The Trade Desk Inc (Symbol: TTD), where a total of 69,953 contracts have traded so far, ...
The average one-year price target for Replimune Group (NasdaqGS:REPL) has been revised to $12.82 / share. This is an increase of 10.52% from the prior estimate of $11.60 dated November 14, 2025. The ...
REPL EFFECT: Repl.it, an online programming and computing platform, has raised $4.5 million in a seed round led by two general partners, Marc Andreessen and Andrew Chen, from the venture capital firm ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results